Biogen Idec’s ALPROLIX™ Therapy for Hemophilia B Granted Approval by Health Canada

Health Canadahas granted approval on Biogen Idec’s (NASDAQ:BIIB) ALPROLIX™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein], a long-acting hemophilia B therapy.

As quoted in the press release:

This is the first regulatory approval worldwide for ALPROLIX, which is currently under review by regulatory authorities in several other countries, including the United States, Australia and Japan.

Biogen Idec CEO, George A. Scangos, Ph.D., said:

Health Canada’s approval of ALPROLIX marks the first significant treatment advance in hemophilia B in 17 years, and reinforces our commitment to developing innovative therapies that help address the critical needs of the hemophilia community. We believe that the safety, efficacy and prophylactic dosing schedule demonstrated with ALPROLIX will provide people with hemophilia B a meaningful new way to manage their condition.

Click here to read the Biogen Idec (NASDAQ:BIIB) press release